Ipca laboratories pvt ltd is globally healthcare partner in over 110 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.
Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments.
Ipca is one of the world's largest manufacturers and suppliers of over a dozen APIs. These are produced right from the basic stage at manufacturing facilities endorsed by the world's most drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.
Ipca is a known therapy leader in India for anti-malarials with a market-share of over 34%. We have leading brands in 5 therapeutic areas, with 4 of our branded formulations being ranked among the Top-300 Indian brands by ORG-IMS.
Our international client roster includes global pharmaceutical giants like AstraZeneca, GlaxoSmithKline, Merck, Roche and Sanofi Aventis are the top most global partners over the years.
At Ipca, quality assurance is an attitude of seeking sustainable betterment in every aspect of our work. The results show in financials as well as work ethic.
Ipca was awarded as 'Among the 100 Best Companies to Work in India in 2010’. In April 2015 Ipca's formulation brand, Zerodol crosses Rs. 200 crores mark.
Ipca has emerging board of directors which include:-
· Premchand Godha-Chairman & Managing Director
· Ajit Kumar Jain -Joint Managing Director
· Pranay Godha-Executive Director
· Prashant GodhaExecutive Director
· Babulal Jain-Director
· Anand T. Kusre-Director
· Dev Parkash Yadava-Director
· Dr. Ramakanta Panda-Director
· Dr. Manisha Premnath-Director
Ipca is among top 10 pharma exporters which has a worldwide presence and divided into 4 categories API, Generics, brand formulations, mission malaria and onyx scientific.
API:-
· One of India’s top exporters of API.
· Lead role in Indian APIs market, in anti-malarial and anti-hypertensive segments.
· First manufacturer in India for APIs like Atenolol, Hydroxycholoquine Sulphate, Morantel Citrate, Pyrantel Pamoate and Zaltoprofen.
Generics:-
· One of India's largest formulation exporters.
· More than half of the formulations backed by own APIs.
· Over 350 formulations in most dosage forms.
· Finished formulations available in over 500,000 retail shops.
Formulations:-
· Ipca manufactures over 350 formulations.
· Our top 10 brands are Zerodol (Aceclofenac + combinations), Lariago (Chloroquine), HCQS (Hydroxychloroquine), Perinorm (Metoclopramide), Rapither (Artemotil), Tenoric (Atenolol + Chlorthalidone), Lumerax (Artemether + Lumefantrine), Etova (Etodolac), Malirid (Primaquine) and Folitrax (Methotrexate).
· This division focuses on the cardiovascular and anti-diabetic segments in markets.
· Formulations account for 67% of export turnover.
· More than half of formulations business backed by own APIs.
· More than 60 formulations brands in over 36 countries.
Mission malaria:-
· Ipca Laboratories Ltd. launched "Mission Malaria" as a social cause, to save over a million lives lost every year.
· Ipca has joined hands with research institutions, foundations, municipalities and other corporate bodies in treating malaria.
· We are India's Market leader in Antimalarial across all dosage forms.
· 18% of current turnover from anti-malarials-around US$ 60mln
· Dedicated anti-malarials marketing division in India-special task force of 500 people.
· Sales of anti-malarial formulations to UNICEF, WHO, IDA, Mission Pharma, PSI, SCMS, MSF, MEG & Ministries of Health in Africa.
· Sale of APIs to AstraZeneca, Pfizer, Bayer, Sanofi Aventis, Dafra, Mepha, Parke Davis among others.
Onyx scientific:-
· Contract research and development.
· Early phase of API manufacturing.
· Late phase and commercial manufacturing.